Hengrui secures $15.2 billion Bristol Myers deal and pivots to co-development with Western partners
Hengrui Pharmaceuticals has become a leading source of innovative drugs in China, outpacing many peers in the current licensing boom.
In May the company signed a $15.2 billion licensing pact with Bristol Myers Squibb, one of the largest agreements ever struck by a Chinese biopharma firm.
Beyond licensing, Hengrui is establishing joint development entities with its Western partners, shifting toward co‑development of new medicines.
Founded in 1970, the Jiangsu‑based firm now employs about 20,000 people, runs 15 R&D centers worldwide, and is listed on both mainland China and Hong Kong exchanges, positioning it for broader global reach.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Hengrui has become the go-to source of China biopharma innovation. What’s its secret?”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that